Aeterna Zentaris announces proposed $15.2 million public offering
This article was originally published in Scrip
Executive Summary
Canadian oncology and endocrinology drug development firm, Aeterna Zentaris has begun a public offering of 6.6 million units, with each unit consisting of one common share and 0.45 of a warrant to purchase one common share, at a purchase price of $2.50 per unit.